Imexpharm Corporation (HOSE:IMP)

Market Cap	7.96T
Revenue (ttm)	2.31T
Net Income (ttm)	309.16B
Shares Out	154.01M
EPS (ttm)	2,007.45
PE Ratio	25.75
Forward PE	n/a
Dividend	500.00 (0.96%)
Ex-Dividend Date	Jun 9, 2025

Volume	213,534
Average Volume	337,368
Open	51,700
Previous Close	51,700
Day's Range	51,700 - 52,100
52-Week Range	30,682 - 56,500
Beta	0.75
RSI	59.78
Earnings Date	Jul 18, 2025

About Imexpharm

Imexpharm Corporation manufactures, processes, trades, imports, and exports pharmaceutical products in Vietnam and internationally. The company’s products include oral and injectable antibiotic, digestion, central nervous system, cardiovascular, diabetes, ophthalmology, musculoskeletal system, respiratory system, analgesic-anti-inflammatory- antipyretics, anti-histamines, anti-allergy, anti-parasitic, and external drugs, as well as vitamins and minerals, and supplement. It is also involved in the import and export of medical equipment and suppl...

• Industry: Pharmaceutical Preparations
• Founded: 1977
• Employees: 1,452
• Stock Exchange: Ho Chi Minh Stock Exchange
• Ticker Symbol: IMP

Financial Performance

In 2024, Imexpharm's revenue was 2.21 trillion, an increase of 10.59% compared to the previous year's 1.99 trillion. Earnings were 297.54 billion, an increase of 16.85%.